Kardigan, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision medicines for cardiovascular diseases with high unmet medical needs. The company's business model centers on in-licensing and advancing late-stage therapeutic candidates that target the underlying pathophysiology of heart conditions, moving beyond traditional symptom management. Kardigan's pipeline includes three primary clinical-stage programs: danicamtiv, an oral cardiac myosin activator for genetic dilated cardiomyopathy (DCM); ataciguat, a soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (CAVS); and tonlamarsen, an antisense oligonucleotide for acute severe hypertension (ASH). A key differentiator for Kardigan is its proprietary "Cardiac Intelligence" platform, which incorporates Prolaio's cardiovascular data collection and analytics technology. This platform utilizes artificial intelligence, FDA-cleared algorithms, and high-density patient data from wearable devices to enhance clinical study design, improve patient responder matching, and track efficacy. By integrating deep cardiovascular biology with advanced analytics, Kardigan aims to accelerate drug development and increase the probability of clinical success. The company operates primarily in the United States, with offices in Princeton, New Jersey, and South San Francisco, California. As a pre-revenue clinical-stage biotech, Kardigan relies on venture capital and public market funding to advance its pipeline toward commercialization.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!